retina
Conditions
Interventions
None listed
Sponsors
Centre for Human Drug Research
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Signed informed consent prior to any study-related procedure. - Male or female subjects aged 50-80 years old. - Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and with a minimum weight of 50 kg. - Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions. - Applicable for Parkinson*s disease patients: Parkinson*s disease patients (Hoehn and Yahr criteria 1-3 at screening), defined as a diagnosis made by a neurologist. - Applicable for Alzheimer*s disease patients: Alzheimer*s disease patients, defined as a diagnosis made by a neurologist or geriatric care specialist, with a score on the Mini Mental State Examination of 24 or higher. - Applicable for diabetic retinopathy patients: diagnosis of diabetes mellitus type 1 or 2 in combination with microvascular retinal damage of any degree visualised with biomicroscopy of the retina. - Applicable for macular degeneration patients: diagnosis of age-related macular degeneration patients, at any stage, apart from end stage wet age-related macular degeneration. - Applicable for glaucoma patients: patients with primary open angle or normal tension glaucoma with mild to severe visual field defects will be selected
Exclusion criteria
Exclusion criteria: - Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history and vital signs (systolic (>150 or 95 or 110 bpm). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance. - For women: pregnant, or breast-feeding, or planning to become pregnant during the study. For participants at the Rotterdam Eye Hospital, this will be ascertained by medical history. For participants at CHDR, an urine pregnancy test will be performed to check for current pregnancies. - For Alzheimer*s disease patients: Inability to willfully sign the informed consent document, supported by an MMSE
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Vascular network • Quantitative scattering & absorption maps at 8 wavelengths o Oxygen saturation map o Blood volume fraction map o Microvascular diameter map o Scattering amplitude map o Wavelength dependence of scattering map • Retinal thickness measurements, in particular the total thickness, RNLF and ganglion cell layer, inner retinal layers • Macular volume | — |
Secondary
| Measure | Time frame |
|---|---|
| n.a. | — |
Countries
Netherlands
Outcome results
None listed